Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Factorial placebo-controlled trial of MKTVIF75HV and ASFSADNS in mild to moderate Alzheimer's disease
ACTRN12606000324516Phase 3Not yet recruiting
- Sponsor
- Melbourne Health
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of Calcirol in Alzheimer's disease (AD) (4 arms), sponsored by Melbourne Health. Primary endpoints: Cognition at 2 months and Memory performance at 48 hours. Planned start Jul 2006; status: not yet recruiting.
02
Drugs
Calcirol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ACTRN12606000324516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000324516.